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Screening Study forFormulation Variables in Preparation and Characterization of 
Candesartan Cilexetil Loaded Nanostructured Lipid Carriers 
 
ABSTRACT 
The current study inspects the screening of the formulation components further, 
evaluates the quality issues of the nanostructured lipid carriers (NLCs) for the 
antihypertensive drug as Candesartan Cilexetil (CC). The sequence screening of all 
excipients required for the preparation of NLCs should be performed.Firstly, the solubility 
of CC in different solid and liquid lipids is the major parameter for the selection of the best 
one. Precirol
®
 ATO 5, Compritol
 ®
 888 ATO andGlyceryl Monostearate (GMS) were 
showed the maximum solubility of the CC (1000 ± 4.12 mg, 1500 ± 4.15 mg and 1750 ± 
3.16 mg), respectively. Hence, they were selected as the solid lipids for the development of 
NLCs. Liquid lipids Transcutol
® 
HP (30 ± 2.21 mg/ml), Labrasol
®
 ALF (25 ± 1.32 mg/ml) 
and Capryol
TM
 90 (18 ± 1.34 mg/ml) were observed to have good affinity for the drug on 
systematic screening of different liquid lipids. However, Precirol
®
 ATO 5 was found to 
hasgood physical compatibility with Transcutol
® 
HP,Compritol ATO 888 was found to 
hashighphysical miscibility with Labrasol
®
 ALF and last GMS was appeared in good 
affinity and compatibly with Capryol
TM
 90. Hence, the following binary lipid mixtures 
(Precirol
®
 ATO 5 - Labrasol® ALF), (Compritol
®
 888 ATO - Transcutol® HP) and (GMS - 
Capryol
TM
 90)were selected for the preparation of NLCs. The liquid–solid lipid mixture in 
the ratio up to 30:70 was observed to have sufficient melting point (55-59 ◦C). LutrolF-68, 
Lutrol F-127, Cremophore EL and Cremophore® RH. In addition to, the combination 
of(Lutrol® F68:Cremophore® EL)and (Lutrol® F127: Cremophore® RH) were selected 
as the main surfactants for the preparation of NLCs formulations because of its good 
emulsification efficacy and homogeneity for the solid-liquid lipid mix. The prepared 
formulationswereinvestigated for the different quality issues. All designed formulations 
observed in nanometer size of particles ranged from (408.9 ± 11.5 to 114.6 ± 8.3 nm) with 
high encapsulation efficiency around 99%.Also, the obtained results revealed that the ZP of 
the various formulations was consistently negative surface charge in between ((-13 ±2.3 
to27.3 ± 3.7 mV). Finally, formula number nine of CC (CC-NLC9) which composed of 
GMS (solid lipid), Capryol
TM
 90 (liquid lipid) and Lutrol® F127: Cremophore® RH 
(surfactants combination) was selected as the best formulation after the rank order for 
further investigations in the next work.   
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1. INTRODUCTION 
Candesartan Cilexetil (CC) is prodrug of candesartan, angiotensin II type 1 (AT1) 
receptor antagonist, widely used in the management of hypertension and heart failure
1,2
. 
Candesartan Cilexetil is radiallyhydrolyzed to active form Candesartan during absorption 
from gastro intestinal tract
3,4
.  
Candesartan Cilexetil owngreatdrawbacks which influence on its oral efficacy and 
therapeutic applicationsuch as very low aqueous solubility and first-pass metabolism. 
Consequently, it has very low oral bioavailability not exceed 15%
2,4–8
. 
To repair previously mentioned drawbacks and to enhance oral bioavailability, 
lipid–based drug delivery systems like nanostructured lipid carrier (NLCs) second type of 
 lipid nanoparticles system can be employed. Lipid nanoparticles systems (LNs) which have 
to generations first, solid lipid nanoparticles (SLN) and second, nanostructured lipid carrier 
(NLCs) canimprove the lymphatic transport of the lipophilic drugs as CC and hence, 
increase its oral bioavailability 
9–11
. LNs systems were recorded as an advanced drug 
carrier system than polymeric nanoparticle
12,13
. 
Advantages of nanostructured lipid carriers (NLCs) over the advantages of 
polymeric nanoparticles because of the lipid component matrix and its properties, which is 
physiologically tolerated. Resulted in avoidance of acute and chronic toxicity. In addition 
to, as good biocompatibility, protection for the incorporated compound against degradation 
and controlled release of drugs 
14
.  
Nanostructured lipid carriers (NLCs) composed of both solid and liquid lipids in 
certain proportion. Therefore, they offer various advantages over solid lipid nanoparticles 
(SLN) such as higher encapsulation efficiency, smaller size and low polymorphic 
changes
11,15–17
 
Generally, nanostructured lipid carriers (NLCs) are nano-drug delivery carrier, 
which own the advantages of polymeric nanoparticles, emulsion, and 
liposomes.Furthermore, (NLCs) are essentially composed of a biocompatible lipid core 
with entrapped lipophilic drugs and surfactant at the outer shell.  
The major aim of this workwas to select aproper excipient for the development of 
NLCs using Candesartan Cilexetil (lipophilic anti-hypertensive agent) as a model drug. 
The screening studies were performed to select the appropriate one of solid lipid, liquid 
lipid and surfactant. Also, investigation of physical compatibilities of solid lipid with liquid 
lipid and the ratios of themwere evaluated. Furthermore, the physical characterization and 
quality issues of developed formulations were described and determined. 
Therefore, this study can offer the sequence steps for the development of NLCs and 
evaluation of their quality characteristics. 
2. Materials and methods 
The active Candesartan Cilexetil (CC) wasobtained as a gift fromMEMPHIS, El-Amirya 
– Cairo –EGYPT. 
Compritol
®
 888 ATO (glyceryldibehenate), Precirol
® 
ATO 5 (Glyceroldistearate type I), 
Maisine
® 
CC (glycerylmonolinoleate), Labrafac
TM
 PG (propylene glycol dicaprylate/ 
dicaprate), Labrafac
TM
 CC (caprylic/ caprictriglycerides), Labrafac
TM
 Lipophile WL 
1349 (medium-chaintriglycerides), Cpryol
®
 90 (propylene glycol monocaprylate type II), 
Lauroglycol
® 
FCC (propylene glycol monolaurate type I), Labrasol
®
 ALF 
(caprylocaproyl macrogol-8-glycerides), Gelucire
®
 44/14 (lauroyl macrogol-32 
glycerides), Gelucire
®
 43/01 (mixtures of mono, di and triglycerideswith PEG esters of 
fattyacids), Gelucire
®
 39/01 pellets (Glycerol esters of saturated C12-C18 fattyacid ester), 
Transcutol
®
 HP (Highlypurifieddiethylene glycol monoethylether), Labrafil
®
 M 1944 CS 
(oleoyl macrogol-6 glycerides), Labrafil
®
 M 2125 CS (linoleoyl macrogol-6-glycerides, 
corn oil PEG-6-ester), Peceol
TM
(glycerylmonooleate),  and Labrafil
®
 M 2130 CS (lauroyl 
macrogol-6-glycerides) werekindlyprovided as a gift samplesfromGattefosse (France). 
Glycerylmonostearate (GMS), Stearicacid, Oleicacid, Soybeanoil, Pluronic® F68 
(polyoxyethylene-polyoxypropylene (150: 29) block copolymer), Pluronic® F127, 
Tween® 80 (polyoxyethylene (20) sorbitanmonooleate), Tween® 40 
(Polyoxyethylenesorbitanmonopalmitate), Carboxymethylcellulose (CMC). 
Phospholipon® 90 G (soy phosphatidylcholine) wasgiven as a gift fromLipoid, 
Ludwigshafen (Germany). 
Cremophor
®
 RH 40 (polyoxyl- 40- hydrogenated castor oil) and Cremophor
®
 EL 
(polyethoxylated castor oil) weresuppliedfrom BASF (Germany). 
Sodium hydroxide, potassium dihydrogen orthophosphate, Potassium Chloride and 
 Hydrochloricacid (HCL) weresupplied by El-Nasr Pharm. Chem. Company, Cairo 
(Egypt). 
Membrane filter (0.45 µm) Millipore Iberica S.A.U. ; Madrid (Spain). 
Methanol and Acetonitrile HPLC grade werepurchasedfrom Sigma Aldrich (USA). 
All the above materials were in analytical grade and were used without further purification. 
2.1. Selection of solidlipid 
The solid lipids screening was carried out by quantification of the saturation 
solubility of CC in different solid lipids which were determined by the test tube 
method. Precisely weighted amount of the CC (100 mg) putted in the test tube then 
the solid lipid was added in increments of (250 mg) to the test tube which could be 
heated to 4-5°C above the melting point of the solid lipid by saving in a controlled 
temperature water bath (Water path 4050, Romo, Cairo, Egypt). The quantity of 
solid lipids required to solubilize the drug in the molten state was recorded. The 
full dissolution state was completed by the formation of a clear, transparent 
solution. 
18–20
. 
2.2. Selection of liquidlipid 
 Screening of liquid lipids were achieved by determination of saturation 
solubility of CC in various oils which was performed by adding an excess amount 
of drug in small glass vials contain fixed volume (5 ml) of different liquid lipids. 
The vials were strictly closed and incubated in adjusted mechanical shaker 
(Oscillating thermostatically controlled shaker, Gallent Kamp, England) for 72 h at 37◦C 
with continuous agitation at 100 rpm 
14,21–24
. Then the mixtures of liquid lipids and 
CC were centrifuged at high speed using (Biofuge Primo centrifuge maximum 17.000 
rpm, England) centrifuge at 10,000 rpm for 15 min. The supernatant was separated and 
dissolved in an appropriate amount of methanol and the drug solubility was determined 
spectrophotometrically using UV-Vis spectrophotometer (Ultraviolet 
spectrophotometer, Shimadzu 1800, Japan) at λ 254nm. 
2.3. Physical compatibility of solid and liquidlipid 
The miscibility of Selected Solidlipids and liquid lipids which possess the 
maximumafﬁnityforthedrug could be achieved. Constant ratio 1:1 of solid lipids and 
liquid lipids were mixed and melted in different glass tubes. The molten binary lipid 
mixture was permitted to solidify at room temperature. After that, the glass tubes were 
determined visually for the absence of divided layers in congealed lipid mass. 
Furthermore, the miscibility between solid lipid and liquid lipid was inspected by 
smearing a cooled sample of congealed lipid mixture onto a filter paper, followed by visual 
observation to clear the presence of any residue of oil on the filter paper. A binary mixture 
distinguished a melting point over 43 
o
C which did not reveal any residue of oil droplets on 
the filter paper was selected for the development of CC – loaded NLCs 11,24–26 
 
2.4. Selection of a binary lipid phase ratios 
The ratio of selected solid lipids and liquid lipids was determined based on 
the meltingpointofthe binary lipid mixture.Selectedsolidand liquid lipids were 
blended in the ratio varying from 90:10 to 10:90, then the binary Lipid mixtures 
were exhibited to be melted and stirred at 200 rpm for 1 h at 5°C above the melting point 
of solid lipid using hot plate  magnetic stirrer (Magnetic stirrer, Wise-stir, Model MSH-
20D, Hot plate stirrer, Korea). Then left to solidify at room temperature. The 
capillary method was used to determine the melting points of the congealed lipid 
mixtures. 
27,28
. 
  
2.5. Selection ofsurfactant 
The surfactant used for fabrication of NLCs should be screened selected 
depending on its ability to emulsify solid-liquid binary lipid mixture. binary lipid 
mixture(100 mg)wasdissolvedin3mLofmethylenechlorideandaddedto10mLof 
5%surfactantsolutionsthen stirred by applyingmagneticstirrer.The organiclayerwas 
evaporatedat40◦Candtheremainingsuspensionsweredilutedwith 10-fold distilled 
water. The transmittance percent of the resultant sampleswasdeterminedusingUV-
Visspectrophotometerat510nm 
22,24,29
. 
2.6. Fabrication of nanostructured lipid carriers (NLCs) 
CC nanostructured lipid carriers (CC-NLC) were prepared by hot homogenization - 
ultrasonication technique but with some few modifications. Briefly, a weighted amount of 
selected solid-liquid binary lipids mixture (5% w/v) was melted at 5 °C above the melting 
point of solid lipid. A known concentration of CC (5 % w/v of lipids) was dissolved in the 
prepared oil phase (5 % w/v mixture of solid and liquid lipid). The aqueous phase 
containing selected surfactant (2.5 % w/v) was heated to the same temperature was added 
drop by drop to the lipid phase under magnetic stirring at 1500 rpm for 5 min. After that, 
homogenization of the resultant pre-emulsion was performed at high speed of mixing about  
20,000 rpm using an Ultra-Turrax T25 homogenizer (WiseMix™ HG15A, Daihan 
Scientific, Seoul, Korea) for 10 min 
27,30–32
. The resultant o/w nanoemulsions were 
subjected to probe sonication (ultrasonic processor, GE130, probe CV18, USA) at 60 % 
amplitude for 10 min. The obtained NLC dispersion was left beside to reach room 
temperature.  
2.7. Physicochemical characterization of CC-NLCs  
2.7.1. Particle size and polydispersity index 
The meandiameter and polydispersity index of particle of nanostructuredlipid 
carriers loadedwith CC wasdeterminedusing a Zetasizer Nano-ZS (Malvern Instruments, 
Worceshtire (UK), equippedwith a 10 mW He-Ne laser employing the wavelength of 633 
nm and a back-scattering angle of 90° at 25 °C. Before Photon correlationspectroscopic 
(PCS) analysis, CC-NLCs formulations shouldbedilutedwith a certain amount of double-
distilled water (1:200) to getappropriatescatteringintensity. The analysis, of Particle size 
wasdeterminedusing Mie theorywith the refractive index and absorbance of lecithin at 
1.490 and 0.100, respectively
33–36
 
 
2.7.2. Zeta potential analysis 
The zeta potential of NLC formulations was measured via electrophoretic mobility 
measurements using a Zetasizer Nano-ZS (Malvern Instruments, Worceshtire (UK). The 
zeta potential was calculated by applying the Helmholtz–Smoluchowski equation (n = 3) 
34,37
. 
2.7.3. Encapsulation efficiency (EE) and loading capacity (LC) 
The encapsulation efficiency and loadingcapacity of CC into NLC formulations 
weremeasured by the indirect method by measuring the concentration of the free CC. 
Initially, 2 ml of NLCs formulations werecentrifuged at 100,000 rpm for 1 h at 4 
◦
C to 
evaluate the unentraped CC usingcooling ultracentrifuge (Beckman Instruments TLX-120 
Optima Ultracentrifuge) 
38–41
. The aqueous layer wasaspirated and filteredusing 
Millipore® membrane (0.2 μm) and dilutedwith an appropriateamount of methanol and 
measured by UV-Vis spectrophotometer (Shimadzu, the model UV-1800 PC, Kyoto, 
Japan) at 254 nm to measure the free amount of CC. Consequently, encapsulation 
 efficiency and loadingcapacity of CC intoNLCsweredeterminedthrough the 
followingequations 
EE% = [(weight of initial drug - weight of free drug) / (weight of free drug)] X 100, 
LC% = [(wt. of drug in nanoparticles) / (wt. of nanoparticles)] X 100. 
 
 
2.7.4. In-vitro drug release study 
The in vitro release of CC from CC suspension and CC-NLCs was performed by a 
dialysis bag diffusion technique. The receptor compartments consist of the following 
release media: 500 ml Hydrochloric acid solution (0.1 N) of pH 1.2 and phosphate buffer 
solution (PBS) of pH 6.8 and again, in the same previous media but with addition 
Polysorbate 20 (0.35%–0.7%w/w) to confirm more achieve sink conditions of dissolution 
media 
42–44
. The donor compartment is cellulose membrane dialysis bags (MWCO‑12 000, 
Sigma, USA) were soaked in dissolution media overnight prior experiment. One milliliter 
of freshly prepared CC‑NLC and CC suspension (equivalent to 2.5 mg of CC) were 
diluted with 5 ml of dissolution media and which tightly closed from two sides by a 
thermo-resistant thread. The bags were immersed in the Dissolution apparatus, (six-spindle 
dissolution tester, Pharmatest, type PTWII, Germany) automatically adjusted at 37 ± 2 °C 
and 100 rpm. Two-milliliter sample was aspirated at a predetermined time interval (0.5, 1, 
2, 4, 6, 8, 10, 12 and 24 h) and the same volume of media was added to maintain sink 
condition. The release of free CC from NLC was compared to that from suspension. The 
aspirated samples were measured using UV-Vis spectrophotometer at 254 nm. 
3. RESULTS and DISCUSSION: 
3.1. Selection of Solid Lipid 
The efficient solubility of the drug in the solid lipid reflects the capacity of NLC 
formulations to accommodate high amount of specific drug 
45
. initially, Candesartan 
Cilexetil (CC) solubility in various solid lipids should be performed to select the 
appropriate ones, which allowed accommodation of high amount of the drug leading to 
maximizing an essential qualification of a carrier system as the loading capacity and 
encapsulation efficiency of the prepared NLC formulations. 
Figure (1) represents the solubility of CC in different solid lipids. The experiments 
with solid lipids demonstrated that the affinity of CC to solid lipid was in order 
ofGelucire
® 
44/14<Precirol® ATO 5 <Compritol ® 888 ATO <Glyceryl Mono Stearate 
(GMS) <Stearic acid <Labrafil® M 2130 CS<Gelucire® 39/01<Gelucire® 43/01 
where,Gelucire
® 
44/14, Precirol
®
 ATO 5, Compritol
®
 888 ATO and Glyceryl Mono 
Stearate (GMS), showed higher CC solubilizing ability, with solid lipid values per 100 mg 
of CC (w/w) of (750 ± 3.11 mg, 1000 ± 4.12 mg, 1500 ± 4.15 mg and 1750 ± 3.16 mg), 
respectively. These results related to the imperfect structure of matrix of Gelucire
® 
44/14, 
Precirol
®
 ATO 5, Compritol
®
 888 ATO and Glyceryl Monostearate (GMS) molecules, 
which are formed due to its chemical nature (mono-, di-, and triglyceride contents) and its 
composition that containing different length of chain of fatty acid that offer loosely porous 
structural features that make the drug easier to modify and more soluble 
46–48
. Gelucire
® 
44/14 is Polyoxylglycerides mixture 
49
, Precirol
®
 ATO 5composed of mixture of 
palmitostearate glyceride and Compritol
®
 888 ATO composition is mixture of behenate 
glyceride;
50
 while Glyceryl Monostearate (GMS) is mixture of variable proportions of 
glyceryl monostearate and glyceryl monopalmitate
49
.  
The variety of Precirol ATO 5
®
fatty acid (C 16 and  C18) content with subsequent 
loosely porous structure and its higher relative monoglycerides content in between 
different solid lipids used (more lipid monoglyceride, more lipid polarity) 
48,51
 In addition, 
 monoglycerides possess emulsification properties 
52
 which can also improve the drug 
solubility, such explain the potentiality of Precirol ATO 5
®
 to solubilize Candesartan 
Cilexetil than Compritol® 888 ATO than GMS.  
Stearic acid, Labrafil
®
 M 2130 CS, Gelucire
® 
39/01, Gelucire
® 
43/01 proved to be 
lower CC solubilizing ability, with solid lipid values per 100 mg of CC (w/w) of (2000 ± 
3.14 mg, 2000 ± 5.12 mg, 2500 ± 3.15 mg and 2750 ± 4.13 mg), respectively, than the 
above mentioned ones. So, the following three solid lipids, Precirol
®
 ATO 5, Compritol
®
 
888 ATO and GMS selected to be used as lipid core for the preparations of CC-NLCs in 
this study after discarding of Gelucire
® 
44/14 because the addition of Gelucire
®
44/14 to 
liquid lipid reduces the melting point of NLCs formulations which was not  appropriate to 
be administered orally 
23,53–55
.. 
3.2. Selection of Liquid Lipid 
Proper dissolvability of CC in Liquid Lipid is basic for the successful formulation 
of nanostructured lipid carrier as well as encapsulation efficiency was directly influenced 
by solubility of the drug in liquid lipid. Screening of liquid lipids was evaluated depending 
on the solubility of CC in different liquid lipids 
5,51,56
. Also, higher drug solubility in the oil 
phase brings down the necessities of surfactants in this way limiting their toxic impacts 
56
. 
The solubility of CC in various liquid lipids were showed in figure (2). 
It was evident that CC revealed highest solubility in peppermint oil (48 ± 2.14mg/ml), 
Transcutol
® 
HP (30 ± 2.21 mg/ml), Labrasol
®
 ALF (25 ± 1.32 mg/ml) and Capryol
TM
 90 
(18 ± 1.34  mg/ml) and the least solubility was observed in Labrafac
TM
 PG (1.1 ± 0.97 
mg/ml),  Labrafac
TM
Lipophil WL 1349 (0.166 ± 0.81 mg/ml) and Labrafac
TM
 CC (0.087 ± 
0.65 mg/ml). The relatively high solubility of (CC) in peppermint oil (48 ± 2.14 mg/ml) 
may be attributed to the composition mixture of peppermint oil with various alcohols, 
ketones and terpenes (menthol, menthone, 1,8-cineole, methyl acetate, methofuran, 
isomenthone, limonene, b-pinene, a-pinene and pulegone) 
57
 that might be aided in 
solubilization of CC through interaction with one or more of the functional groups of CC 
(such as –NH and –C=O). Furthermore, surface active properties of components of 
peppermint oil (HLB = 12.3) 
58
.  
The solubilization ability of Transcutol
® 
HP (30 ± 2.21 mg/ml), Labrasol
®
 ALF (25 
± 1.32 mg/ml) and Capryol
TM
 90 (18 ± 1.34  mg/ml) for CC was attributed to their intrinsic 
self-emulsifying property and their chemical structure  (PEG-medium chain triglycerides) 
because of the affinity of a broad range of hydrophilic and lipophilic drug molecules to be 
encapsulated into lipid carriers, increased with PEG-glycerides than that glycerides free 
from PEG moieties such as (Labrafac
TM
 PG, Labrafac
TM
LipophilandLabrafac
TM
 CC) due 
to their known surfactant properties 
39,59
.  
The high solubilizing effect of Transcutol® HP for CC is consistent with Cirri et al., 
2018 
29
. Furthermore, presence of Caprylic acid (C8) in oil composition had great 
impaction on drug solubility, where the oils of the more Caprylic acid content were found 
to be the higher solubilizing one for drug such as  (Caprylic acid content in Labrasol
®
 ALF 
and Capryol 90) are 80 and 90%, respectively,  
60
. This phenomenon may be attributed to 
the Caprylic acid polarity making it more efficient solubilizing one for the poorly water-
soluble drug. Thus, Transcutol® HP, Labrasol® ALF and Capryol
TM
 90 were selected as a 
liquid lipid for further investigation because of the high solubilizing extent of CC after 
discarding of peppermint oil due to the low of its flashpoint (66.1°C) than the temperature 
that needed during the formulation preparation process.  
3.3. Physical Compatibilities between Solid lipid and Liquid lipid 
 An essential for the improvement of a stable NLC development and permits taking 
into account that the fluid lipid is completely entrapped inside solid lipid matrix thus, 
 physical compatibility between solid lipids and liquid lipids must be achieved 
61,62
. All 
three selected solid lipids (Precirol
®
 ATO 5, Compritol
®
 888 ATO and GMS) were further 
evaluated for the physical compatibility with three selected liquid lipids (Transcutol® HP, 
Labrasol® ALF and Capryol
TM
 90) by applying visual and filter paper examination. The 
obtained results indicate that (Precirol
®
 ATO 5 - Transcutol® HP) and (Precirol
®
 ATO 5 - 
Capryol
TM
 90) mixtures showed phase separation and residue of liquid oil droplets on filter 
paper indicating formation of inhomogeneous mixtures (data not shown). The reduction in 
the melting temperature of the combined lipid mixtures was the reason for such 
observation. 
On the other hand, no presence of more than one layer was observed in the 
solidified mass and no residue of liquid lipid droplets on the filter paper of (Precirol
®
 ATO 
5 - Labrasol® ALF) mixture indicate that formation of homogenous mixture. These results 
are consistent with S. Doktorovov et al 2010 
59,63
. However, (Compritol
®
 888 ATO - 
Labrasol® ALF) and (Compritol
®
 888 ATO - Capryol
TM
 90) mixtures also showed phase 
separation and presence of liquid oil droplets on filter paper indicating formation of 
inhomogeneous mixtures. Such an observation could be attributed to the same previous 
reason mentioned above.  
On the other side, there was no separation was showed in the congealed mass and 
no residue of liquid oil droplets on filter paper of (Compritol
®
 888 ATO - Transcutol® HP) 
mixture indicate that formation of homogenous mixture. While, GMS as solid lipid showed 
good miscibility and homogeneity with all three selected liquid lipids (Transcutol® HP, 
Labrasol® ALF and Capryol
TM
 90). Therefore, based on the screening study of the solid 
and liquid lipids for CC and physical compatibility between two types of lipids, (Precirol
®
 
ATO 5 - Labrasol® ALF), (Compritol
®
 888 ATO - Transcutol® HP) and (GMS - 
Capryol
TM
 90) mixtures were selected as solid and liquid lipids, respectively for further 
investigation. Since Precirol
®
 ATO 5 is one of three selected solid lipids has a high affinity 
for the CC was found to has also good compatibility for Labrasol® ALF liquid lipid. While 
Compritol
®
 888 ATO sloid lipid has a high affinity for CC was found to has good 
compatibility for Transcutol® HP liquid lipid and GMS solid lipid has a high affinity for 
CC was found to has good compatibility for Capryol
TM
 90 liquid lipid while the remained 
lipids were excluded from further designing of the formulation.  
3.4. Determination of the SL: LL ratios using melting point technique 
 solid-liquid lipids proportion was chosen with the goal to have enough drug loading 
capacity with a legitimate liquefying point to keep up the solid-semisolid uniformity of the 
particles at room temperature. As (Transcutol® HP, Labrasol® ALF and Capryol
TM
 90) 
were seen to have good drug solubilization limit, a higher proportion of (Transcutol® HP, 
Labrasol® ALF and Capryol
TM
 90) as liquid lipids could be helpful for the higher drug 
encapsulation 
24
. In any case, at the same time, the consistency of the (solid-liquid) lipids 
blend can't be undermined. It was seen that the (solid-liquid) lipids blend in the proportion 
up to 70:30 were having an adequate melting point (55 – 59◦C) (data not shown). 
Furthermore, the increment of liquid lipid concentration, the melting point of the blends 
were beneath the ideal level. In addition, 70:30 the most appropriate and common ratio and 
widely applied by most previous related studies 
37,64–67
. Consequently, 70:30 was chosen as 
the proper preparing ratio for the solid-liquid lipid mixture in all NLC formulations. 
3.5. Screening study of surfactants: assessment of dispersion properties 
 The most important character for surfactant selection is the ability and capacity of 
surfactant to emulsify the produced emulsion with keeping its stability. A higher 
transmission rate is consistent with smaller particles and therefore greater emulsification. 
22
. Furthermore, The surfactant plays a necessary role in stabilization of NLC by 
 decreasing the interfacial tension between the aqueous phase and the lipid phase of 
nanoemulsion and thus inhibits coalescence and agglomeration of particles 
39,68
.  
As depicted in the table (1). results revealed that Lutrol® F68 showed maximal 
emulsification capacity for binary lipids of three selected lipid mixtures (Precirol
®
 ATO 5 - 
Labrasol® ALF), (Compritol
®
 888 ATO - Transcutol® HP) and (GMS - Capryol
TM
 90) 
where (98.106 ± 5.3, 97.324 ± 7.2 and 98.685 ± 5.2% transmittance), respectively. 
Followed by Lutrol® F127 (97.972 ± 8.1, 95.079 ± 1.4 and 95.004 ± 8.1 % transmittance). 
Then, Cremophore® EL (94.756 ± 3.3, 89.438 ± 1.3 and 86.475 ± 5.3 % transmittance) 
and last Cremophore® RH (81.847 ± 9.1, 82.680 ± 6.3 and 78.185 ± 6.7% transmittance).  
On the other hand, binary selected lipid mixtures mentioned above exhibited poor 
emulsification and formed turbid nanoemulsion with Phospholibon® (19.890 ± 7.3, 10.350 
± 4.3 and 30.989 ± 8.3 % transmittance), respectively.The transmittance percentage which 
clearly distinguished and reflect the ability of surfactants to emulsify and stabilize binary 
selected lipid mixtures. Where a high percentage of transmittance indicates enough 
emulsified and stabilized emulsion. This fact is attributed to the hydrophilic-lipophilic 
balance (HLB) value of surfactant used, which results in high HLB values accompanied by 
higher transmission lead to smalle particles. 
23,69
.HLB values of surfactants used in 
screening studies are in order of  lutrol® f68 (HLB = 29)  <lutrol® f127 (HLB = 23) 
<Cremophore® RH (HLB = 14-16) < Tween® 40 (HLB = 15.4) < Tween® 80 (HLB = 15) 
<Cremophore® EL (HLB = 12-14) <Phospholibon® (HLB = 8) 23,70,71. Phospholibon® 
was a poor sufficient to emulsify the selected binary lipid mixture because it has a low 
value of HLB which was not adequate for o/w emulsion formation 
72
.  
Despite there were no major variation of HLB values of the most surfactant used, 
Cremophore® EL (HLB = 12-14) had high emulsification effect than Cremophore® RH 
(HLB = 14-16), Tween® 40 (HLB = 15.4) and Tween® 80 (HLB = 15). Apart from HLB 
value, there were another factor such as the chemical structure of surfactants had a great 
impaction on the nanoemulsification process. Tween® 80 is derived from 
polyoxylatedsorbitan and oleic acid. Cremophor® EL is polyethoxylated castor oil, which 
is a mixture of polyethylene glycol ethers and polyethylene glycol esters of glycerol and 
ricinoleic acid. Cremophor® EL possesses a branched structure of alkyl chain, whereas 
Tween® 80 possesses a linear shape structure. The obtained results were in confirmation 
with Borhade et al 2012, 2008 and Kassem et al 2017 
73–75
 stated that surfactants whose 
branched alkyl structure had good emulsification properties on nanoemulsion formation. 
Therefore, based on the emulsification ability of surfactants for selected binary lipid 
mixtures, Lutrol® F68, Lutrol® F127, Cremophore® EL, Cremophore® RH, Tween® 40 
and Tween® 80 were selected for further investigation as surfactant combination study. 
3.6. Screening study of surfactants combination: assessment of dispersion properties 
From previous literature, it was clearly distinguished that the kind and quantity of 
surfactant influence the size of the nanoparticles and their storage stability. The quantity of 
surfactant should be enough to cover the surface of the hydrophobic nanoparticles 
39,76
. The 
combination of two or more surface-active agents exhibits to form blended surfactant films 
at the surface of the particle size. The formed blended surfactant films were produced in 
sufficient amount to  cover the surface of particles successfully and produce nanoparticles 
with small size as well as keeping storage stability by production of requisite viscosity 
22,77–79
.  
In present art, it was observed in table (2) 1:1 ratio of Lutrol® f127 and 
Cremophore® RH showed good emulsification ability and promote nanoemulsion stability 
of first binary lipids mixture (Precirol
®
 ATO 5 - Labrasol® ALF), combination of selected 
surfactants in ratio as the same previous exhibited poor emulsification properties of second 
binary lipids mixture (Compritol
®
 888 ATO - Transcutol® HP) while combination of 
 selected emulsifying agent at the mentioned above ratio (Lutrol® f68 and Cremophore® 
EL) and  (Lutrol® f127 and Cremophore® RH) showed the higher emulsification 
capability as well as stability of emulsion of third binary lipids mixture (GMS - Capryol
TM
 
90).  
 
The obtained results may be attributed to the same reasons mentioned above under 
explanation of screening study of surfactants wherein the hydrophilic-lipophilic balance 
(HLB) value of the surfactant play a great  role in this fact 
23,70,71
. Also, branched alkyl 
chain structure, as well as the length of hydrophobic chains of surfactants, had a countless 
effect on the nanoemulsion formation 
73–75
 as Cremophore® EL and Cremophore® RH. 
hence, based on the introduced emulsification study of surfactants, Lutrol® F68 
andLutrol® F127 were selected as surfactants for every binary lipid mixture for the 
preparation of NLC. Addition to (Lutrol® f127: Cremophore® RH) at equal ratio for 
(Precirol
®
 ATO 5 - Labrasol® ALF) binary lipid mixture and (Lutrol® f68: Cremophore® 
EL) and (Lutrol® f127: Cremophore® RH) at equal ratio for (GMS - Capryol
TM
 90) binary 
lipids mixture as surfactant combination for preparation of NLC. 
3.7. Fabrication of CC-NLCs 
Based on screening and solubility studies, the NLC formulations were designed, 
formulated and improved using lipid phase composed of Precirol® ATO 5, Compritol® 
888 ATO and GMS as solid lipid and Labrasol® ALF, Transcutol® HP and Capryol
TM
 90 
as liquid lipid which were chosen based on CC solubility in the lipid phase. Lutrol® F68, 
Lutrol® F127, Cremophore® EL and Cremophore® RH as surfactants which constituted 
the aqueous phase. The concentration of the lipid phase to surfactant was constant at 5% 
(w/w) and 2.5% (w/w), respectively and the concentration of CC was fixed to 5% (W/W) 
of the lipid phase. The lipid phase should not be exceedingly beyond 5% w/w. The 
observations are in line with studies reported by Das et al 2012 and Elbahwy et al 2017 
72,80
 who discovered that an increased concentration of lipid leads to an enormous increase 
of particle size. As formulations are designed to be orally used, surfactants have been 
established at a pleasant 2.5% concentration (w / w) 
81
. The composition of the formulation 
is given in the table (3). Preparation of CC-NLCs were performed using homogenization 
followed by probe sonication technique. the influence of the lipids and surfactants 
variation on the particle size and the PDI was studied. also, other physical characterization 
should be achieved for every formulation to select the best one for further investigations. 
3.8. Physicochemical characterization of CC-NLC formulations  
3.8.1. Particle size, polydispersity index (PDI) 
Determination of physical properties as particle size and PDI are essential for 
predicting the stability of NLCs formulations.Particle sizing is a significant method for 
confirming nanosized particle manufacturing. Also, the smallest particle size, the more 
absorbable and uptake through the gastrointestinal tract. then, efficiently phagocytosed by 
the reticuloendothelial system. Therefore, the accuracy in particle size evaluation was 
necessary. Usually, the recommended particle size requisite for transportation through the 
intestine should not be more than 300 nm 
82,83
.  
As represented in table (4) and figure (3) the observations revealed that all the 
designed formulations were showed in the nanometer range (<408 nm). It can be 
concluded that particle size of Precirol® ATO 5 nanoparticles (F1 to F3), Compritol® 888 
ATO nanoparticles (F4 and F5) and GMS nanoparticles (F6 to F9) ranged from (280.6 ± 
11.8 to 118.6 ± 8.1 nm), (283 ± 9.9 and 196.5 ± 10.2 nm) and (408.9 ± 11.5 to 114.6 ± 8.3 
nm), respectively. The obtained results were clearly distinguished that formulations that 
contain more than one surfactant give the small particle size than that contain one 
surfactant as in F3 and F9 (118.6 ±8.1 and 114.6 ±8.3 nm) this behavior was attributed to 
 the same reason discussed above under the screening study of surfactants combination. 
Also, these results were in accordance with the following reported studies 
22,77–79,83
.  
On the other hand, the largest particle size was exhibited in GMS formulations 
which contain surfactant Lutrol® F68 alone or in combination with other surfactants as in 
F6 and F8 (408.9 ± 11.5 and 392.1 ± 13.8 nm). This observation may be attributed to the 
tendency of GMS nanoparticles to form a gel after 24 h storage at room temperature due to 
polymorphic transitions in GMS after cooling at room temperature. Furthermore, the 
interaction between GMS and Lutrol® F68. The polymorphic transitions in the lipids after 
cooling to the room temperature and the interaction between surfactant and lipid are known 
to cause gel formation and subsequently influence the PS in NLC and SLN dispersions 
84,85
.  
The polydispersity index as an indicator of the size distribution width of the 
particle. The PI value that reflects dispersion quality typically varies between 0 and 1. 
Most researchers recognize PI values ≤ 0.3 as optimum values; however, values ≤ 0.5 are 
also acceptable 
86
. Table (4) and figure (3) give an overview of the results of polydispersity 
index measurements. The prepared NLC dispersions had a PI value ≤ 0.35 ± 0.01 due to 
the preparation method used indicating a homogenous and narrow size distribution of 
nanoparticles of NLCs.  
3.8.2. Zeta potential (ζ) measurement 
The main parameter which influences the storage stability of colloidal nanocarrier 
is zeta potential, which measures the nanoparticle's surface charge and provides the 
repulsion degree between the nanoparticles preventing its agglomeration 
87,88
. From the 
factors which mainly influence zeta potential of lipid-based nanoparticles structure of solid 
and liquid lipid and the medium composition 
65,88
. Also, it depends on higher steric 
stabilization and lowers an electrostatic stabilization of nonionic surfactants which 
perfectly forming a coat around the particles of NLCs. Result in surface coverage of NLC 
decreases the electrophoretic mobility of nanoparticles and thus lower the zeta potential 
values 
6,36,38,81,89
. This phenomenon explains the higher stability of NLC formulations 
despite having a lower zeta potential value. 
Zeta potential values ofall designed formulations are shown in table (4) and 
represented in figure (4). The results revealed that the ZP of the various formulations was a 
consistently negative surface charge. ZP values of Precirol® ATO 5 nanoparticles (F1 to 
F3), Compritol® 888 ATO nanoparticles (F4 and F5) and GMS nanoparticles (F6 to F9) in 
between (-13 ±2.3 to -17.8 ± 2.8 mV), (-18.1 ± 2.4 and -18.7 ± 1.7 mV) and (-18.9 ±1.9 to 
27.3 ± 3.7 mV), respectively. Due to the non-ionic behavior of used surfactants for 
stabilization of nanoparticles so, these molecules had not any role in the obtained zeta 
potential charges. Furthermore, the solid lipids were used in developed NLCs composed of 
mixture of acylglycerols: Precirol® ATO 5 composed ofglyceryl tripalmitostearate (25% - 
35%), glyceryl dipalmitostearate (40% - 60%) and glyceryl monopalmitostearate (8% - 
22%) 
49,90
 and Compritol® 888 ATO composed of glyceryl tribehenate (28% - 32%), 
glyceryl dibehenate (52% - 54%) and glyceryl monobehenate (12% - 18%) 
49,88
, both of 
them being glycerol esters of long chain-length fatty acids (C18, C16) and (C22) 
respectively. So, that they provide neither charge nor polarity that participates to zeta 
potential. whereas, GMS composed of triacylglycerols (5 – 15%), diacylglycerols (30 – 
45%) and monoacylglycerols (40 – 55%) 49. In such a case due to the high content of 
partial emulsifying glycerides (mono and diglycerides) of GMS and the presence of non-
esterified hydroxyl groups of glycerol, this molecule showed some of the polarity that 
participates to zeta potential. 
On the other hand, the liquid lipids were used in developed NLCs composed of 
diacylglycerol of medium-chain-length fatty acids. Liquid lipids provide the majority 
impaction and contribute to zeta potential due to its polarity which results from a free 
 hydroxyl group of the glycerol that not subjected to the esterification process and the chain 
length of the fatty acids. These observations are in line with studies reported by 
Teeranachaideekulet al, 2008and López-García and Ganem-Rondero, 2015
88,91
 which 
stated that it might be due to presence of liquid lipid at the surface of NLC. Being the 
melting point of liquid lipid lower than that of the solid lipid, during the fabrication process 
of NLC, the solid lipid recrystallizing again first, with encapsulating an apart of the liquid 
lipid inside the solid lipid matrix. Subsequently, the remained amount of liquid lipid was 
covered the outer layer of formed nanoparticles 
59,92
.  
The obtained results can be concluded that GMS nanoparticles (F6 to F9) possessed 
high zp values than that of Precirol® ATO 5 nanoparticles (F1 to F3) and Compritol® 888 
ATO nanoparticles (F4 and F5) this fact can be explained by the following reasons: certain 
polarity and emulsifying properties of GMS resulted from none esterified hydroxyl group 
of glycerol and the length of chain of the fatty acids. Another reason was attributed to the 
negative charged carboxylic groups of MCT (capryol
TM
 90) which composed mainly 
monoesters and a small fraction of diesters of caprylic/capric triglyceride. A similar 
explanation has been reported by Teeranachaideekul et al,  2007 
93
, these revealed the 
higher ZP values of GMS nanoparticles than other nanoparticles. 
3.8.3. Entrapment Efficiency, Drug Content and Drug Loading of CC-NLCs 
The quantity of drug encapsulated in the nanoparticles and the drug content in the 
lipid matrix is a further significant consideration for the optimization of NLC. The quantity 
of drug encapsulated in the lipid matrix depends on many factors as: the type of lipids 
used, physicochemical properties of the drug,  miscibility and solubility of drug in the 
molten lipid 
94
, physical and chemical nature of the lipid matrix and crystalline state of 
lipid matrix and also surfactant was found to affect encapsulation efficiency 
38,46,95
.  
Encapsulation efficiency and loading capacity of all NLC formulations are showed 
in the table (5) and demonstrated in figure (5). The entrapment efficiency and drug loading 
were determined and found to be in between 94.76 ± 2.44 % to 99.80 ± 2.50% and 0.55 ± 
0.11% to 5.10 ± 0.19%, respectively. These high entrapment efficiencies and drug loading 
of CC in NLCs could be attributed to the high lipophilic nature of CC (log p ~ 6.2) which 
enhance the solubility of CC in various lipids and subsequently easily incorporated into the 
lipid matrix 
6,96
. Moreover, the using of a mixture of perfect ordered with less ordered 
lipids, which caused several crystal defects in lipid matrix and provided much 
imperfections leading to void spaces in which more drug molecules could be  
accommodated 
14,38,83,96
. 
It was observed that E.E and LC of CC in Precirol® ATO 5 nanoparticles (F1 to 
F3) were varied from 98.5 ± 2.70% to 99.8 ± 2.50 and 1.03 ± 0.10 to 1.32 ± 0.21, 
respectively, in Compritol® 888 ATO nanoparticles (F4 and F5) were varied from 99.04 
±2.35 to 99.30 ± 2.25% and 0.82 ± 0.13 to 0.55 ± 0.11, respectively and in GMS 
nanoparticles (F6 to F9) also were ranged from 94.76 ± 2.44% to 95.94 ± 3.45% and 3.92 
± 0.31% and 5.10 ± 0.19%, respectively. From the results, it was clearly distinguished that 
Precirol® ATO 5 nanoparticles (F1 to F3) and Compritol® 888 ATO nanoparticles (F4 
and F5) showed higher entrapment efficiency around 99% than that of GMS nanoparticles 
(F6 to F9) around 95%. Such a fact was attributed to the chemical composition of each 
one. Where, the imperfect and less ordered matrix structure of Precirol® ATO 5 and 
Compritol® 888 ATO molecules, which are formed from a combination of mono-, di- and 
triglyceride that expected to exhibit lower crystallinity and more structure  porosity which 
allows higher solubility and easier accommodation of more drug molecules 
23,45
. Also, 
Precirol® ATO 5 is a di-glyceride with two different chain length fatty acids palmitic and 
stearic acid (C16 and C18); therefore, it is expected to have less ordered lipid network 
compared to GMS, and thus lead to the more drug molecules could be entrapped 
23,47,54
. 
 Further, subsequent to cooling, Precirol® ATO 5 and Compritol® 888 ATO recrystallize 
in a progression of polymorphs. In like manner, with respect to the conditions utilized 
during the preparation, CC could be homogenously dispersed 
38
. 
Regarding the type of surfactant, it was clearly observed that NLCs formulation 
prepared using Lutrol® F68 higher E.E. than that prepared using other surfactants. This 
behavior repeated with every nanoparticle prepared using Lutrol® F68 alone (F1, F4 and 
F6) or in combination with Cremophore® EL (F8). This fact might be attributed to the high 
value of the hydrophilic-lipophilic balance of Lutrol® F68 (HLB ~ 29) compared to other 
surfactants. 
3.8.4 In-vitro release study 
In-vitro release study was achieved for all formulations in addition to pure CC 
suspension. The release condition monitored in 0.1 M HCl (pH 1.2) and PBS (pH 6.8) and 
at the same conditions with adding tween 20 (0.35%–0.7%w/w) to achieve “sink” 
conditions during a dissolution test for all formulations 
43,97
. It was found that all 
formulations exhibit a lack of drug release within 24 h except CC suspension showed 
almost complete drug release (100%) within 8 h. As CC had solubilities equal to 11 μg/mL 
in 0.1 M HCl and 1 μg/mL in PBS (pH 6.8)8,98, the very difficult release of CC results from 
its poor aqueous solubility and high lipophilicity (log p ~ 6.2). Thus, CC possesses a high 
affinity to the lipids consequently the drug becomes more entrapped and retained inside the 
core of the lipid matrix preventing it from the release. Furthermore, the high efficient 
solubility and compatibility of CC with the lipid components as previously discussed 
before under screening studies 
8,99
. These observations are in line with the study reported 
by Zhang et al 2012 
8
. Previous studies ascertained that NLCs must be absorbed into the 
blood or lymphatic system after duodenal administration to rates 
100
. Consequently, lack of 
in-vitro release of CC from NLCs suggesting that NLCs could be absorbed via the 
enterocytes after oral administration, the most sought-after therapeutic effect.which 
required conformation through employing more investigations in next work. 
The rank order was performed for all prepared NLCs formulations (F1 to F9) in 
order to choose the best formula based on the previously measured characterization as 
Particle size, polydispersity index (PDI), zeta potential (ζ), encapsulation efficiency and 
loading capacity of CC-NLCs wherein the formula F9 was chosen as the best formula for 
further investigations. 
4. CONCLUSION 
Nanostructured lipid carriers (NLCs) are adaptable nanoparticles with multipurpose 
applications. However, quality and successful incorporation of CC into NLC to develop 
more efficient formulation based on proper selection of the components and optimization. 
The current workclarifies a sequence steps for selection of excipients for NLCs by 
employing simple experiments.  
screening studies were performed for whole excipients to select appropriate ones to prepare 
CC loaded NLCs. 
Furthermore, the developed formulations were subjected to physicochemical 
characterization. The resulted formulations appeared in nanoparticle size with high 
encapsulation efficiency. 
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Tables  
Table (1): Miscibility study of binary lipid mixtures with different surfactants 
SL: LL in ratio 
SAA 
10 ml of 5% soln. 
Transmittance ± SD % 
 
Precirol® ATO 5:  
Labrasol
®
 ALF 
Lutrol® F68 98.106 ± 5.3 
Lutrol® F127 97.972 ± 8.1 
Cremophore®EL 94.756 ± 3.3 
Cremophore®RH 81.847 ± 9.1 
Tween® 40 69.650 ± 1.8 
Tween® 80 65.850 ± 2.3 
 Phospholibon® 19.890 ± 7.3 
Compritol
®
 ATO 888: 
Transcutol
® 
HP 
Lutrol® F68 97.324 ± 7.2 
Lutrol® F127 95.079 ± 1.4 
Cremophore®EL 89.438 ± 1.3 
Cremophore®RH 82.680 ± 6.3 
Tween® 40 67.435 ± 3.3 
Tween® 80 67.256 ± 7.2 
Phospholibon® 10.350 ± 4.3 
GMS: Capryol
TM
 90 
Lutrol® F68 98.685 ± 5.2 
Lutrol® F127 95.004 ± 8.1 
Cremophore®EL 86.475 ± 5.3 
Cremophore®RH 78.185 ± 6.7 
Tween® 40 75.443 ± 6.3 
Tween® 80 69.481 ± 9.2 
Phospholibon® 30.989 ± 8.3 
 
 
Table (2): Miscibility study of binary lipid mixtures with combinations of surfactants 
SL: LL in ratio 
SAA Combination (1 :1) 
10 ml of 5% soln. 
Transmittance % 
Precirol
®
 ATO 5:  
Labrasol
®
 ALF 
 
Lutrol® F68:  
Tween® 40 
53.8 ± 6.7 
Lutrol® F127:  
Tween® 40 
50.2 ± 9.5 
Lutrol® F68:  
Cremophore® EL 
18.0 ± 7.3 
Lutrol® F127:  
Cremophore® RH 
89.8 ± 8.5 
 
Compritol
®
 ATO 888:  
Transcutol
® 
HP 
Lutrol® F68:  
Tween® 40 
71.0 ± 5.2 
Lutrol® F127:  
Tween® 40 
59.0 ± 4.3 
Lutrol® F68:  
Cremophore® EL 
54.1 ± 7.3 
Lutrol® F127:  
Cremophore® RH 
26.7 ± 8.9 
GMS: Capryol
TM
 90 
 
Lutrol® F68:  
Tween® 40 
28.3 ± 4.4 
Lutrol® F127:  
Tween® 40 
23.2 ± 8.7 
 Lutrol® F68:  
Cremophore® EL 
98.2 ± 7.3 
Lutrol® F127:  
Cremophore® RH 
96.7 ± 6.3 
 
 
 
 
Table (3): Suggested formulae of CC-NLCs 
F 
No. 
SL (70%) LL (30%) 
SAA (2.5%) of Total 
Formula 
(g) 
Drug 
(5%) 
of 
Lipids 
(mg) 
Water 
(92.5%) 
(g) 
(5%) of Total Formula 
(g) 
P C GMS L T Cp 
L 
F68 
L 
F127 
L 
F127 
+ Cr 
RH 
(1:1) 
L 
F68 
+ Cr 
EL 
(1:1) 
CC 
F1 3.5   1.5   2.5    250 92.5 
F2 3.5   1.5    2.5   250 92.5 
F3 3.5   1.5     2.5  250 92.5 
F4  3.5   1.5  2.5    250 92.5 
F5  3.5   1.5   2.5   250 92.5 
F6   3.5   1.5 2.5    250 92.5 
F7   3.5   1.5  2.5   250 92.5 
F8   3.5   1.5    2.5 250 92.5 
F9   3.5   1.5   2.5  250 92.5 
SL = Solid lipid, LL = Liquid lipid, SAA = Surface active agent, P = Precirol®ATO 5, C = 
Compritol®ATO 888, GMS = Glyceryl Monostearate, L = Labrasol
®
 ALF, T = Transcutol
® 
HP, Cp = Capryol
TM
 90, L F68 = Lutrol® F68, L F127 = Lutrol® F127, Cr RH = 
Cremophore®RH, Cr EL = Cremophore®EL, CC = Candesartan Cilexetil. 
 
 
Table (4): Particle size, polydispersity indices and zeta potential of CC-NLCs formulations 
Formula No. PS (nm) PDI ZP (mV) 
F1 280.6 ± 11.80 0.32 ± 0.01 -17.8 ± 2.80 
F2 210.7 ± 9.10 0.32 ± 0.01 -13.0 ± 2.30 
F3 118.6 ± 8.10 0.35 ± 0.03 -13.9 ± 1.50 
F4 283.0 ± 9.90 0.22 ± 0.07 -18.1 ± 2.40 
F5 196.5 ± 10.20 0.26 ± 0.05 -18.7 ± 1.70 
F6 408.9 ± 11.50 0.28 ± 0.09 -18.9 ± 1.90 
F7 141.8 ± 7.10 0.22 ± 0.07 -23.8 ± 2.90 
F8 342.1 ± 13.80 0.21 ± 0.04 -24.2 ± 3.50 
 F9 114.6 ± 8.30 0.21 ± 0.04 -27.3 ± 3.07 
 
 
 
 
 
 
 
Table (5): Encapsulation efficiency and loading capacity of CC-NLCs formulations 
Formula No. E.E. (%) L.C. (%) 
F1 99.80 ± 2.50 1.03 ± 0.10 
F2 98.70 ± 3.40 1.12 ± 0.35 
F3 98.50 ± 2.70 1.32 ± 0.21 
F4 99.30 ± 2.25 0.55 ± 0.11 
F5 99.04 ± 2.35 0.82 ± 0.13 
F6 95.94 ± 3.45 3.92 ± 0.31 
F7 95.04 ± 3.40 4.82 ± 0.11 
F8 95.56 ± 2.50 4.30 ± 0.12 
F9 94.76 ± 2.44 5.10 ± 0.19 
 
 
 
Figures  
 
 
 Figure (1):Solubility study of CC in different solid lipids 
 
 
Figure (2):Solubility study of CC in different liquid lipids 
 
Figure (3): Mean particles size and polydispersity index of CC-NLCs formulations 
 
 
 
  
Figure (4): Zeta potential of CC-NLCs formulations 
 
 
 
 
Figure (5): Encapsulation efficiency and loading capacity of CC-NLCs formulations 
 
 
 
